APP and Alzheimer disease: In the latter cases, the anti-inflammatory treatment would act preventively prior to the onset of AD (i.e., prior to the activation of the AβPP-independent iAβ production pathway), whereas, following its commencement, the transient implementation of the ACH2.0-based drugs should be combined with the long-term anti-inflammatory therapy.